On Friday, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) was -10.08% drop from the session before settling in for the closing price of $262.16. A 52-week range for ALNY has been $141.98 – $304.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 63.53% over the past five years. When this article was written, the company’s average yearly earnings per share was at 22.09%. With a float of $124.36 million, this company’s outstanding shares have now reached $129.29 million.
Let’s look at the performance matrix of the company that is accounted for 2230 employees. In terms of profitability, gross margin is 85.62%, operating margin of -7.87%, and the pretax margin is -16.79%.
Alnylam Pharmaceuticals Inc (ALNY) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Alnylam Pharmaceuticals Inc stocks. The insider ownership of Alnylam Pharmaceuticals Inc is 4.40%, while institutional ownership is 95.02%. The most recent insider transaction that took place on Mar 24 ’25, was worth 1,633,500. In this transaction CMO & EVP Dev & Med Affairs of this company sold 5,445 shares at a rate of $300.00, taking the stock ownership to the 20,221 shares. Before that another transaction happened on Mar 21 ’25, when Company’s CMO & EVP Dev & Med Affairs sold 4,321 for $285.00, making the entire transaction worth $1,231,485. This insider now owns 20,221 shares in total.
Alnylam Pharmaceuticals Inc (ALNY) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.09% per share during the next fiscal year.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Trading Performance Indicators
You can see what Alnylam Pharmaceuticals Inc (ALNY) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.17, a number that is poised to hit -0.90 in the next quarter and is forecasted to reach 1.54 in one year’s time.
Technical Analysis of Alnylam Pharmaceuticals Inc (ALNY)
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) saw its 5-day average volume 1.15 million, a positive change from its year-to-date volume of 0.81 million. As of the previous 9 days, the stock’s Stochastic %D was 17.06%. Additionally, its Average True Range was 13.33.
During the past 100 days, Alnylam Pharmaceuticals Inc’s (ALNY) raw stochastic average was set at 8.28%, which indicates a significant increase from 0.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.01% in the past 14 days, which was higher than the 47.55% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $259.45, while its 200-day Moving Average is $258.05. Nevertheless, the first resistance level for the watch stands at $251.41 in the near term. At $267.08, the stock is likely to face the second major resistance level. The third major resistance level sits at $275.00. If the price goes on to break the first support level at $227.82, it is likely to go to the next support level at $219.90. The third support level lies at $204.23 if the price breaches the second support level.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Key Stats
There are 130,085K outstanding shares of the company, which has a market capitalization of 30.67 billion. As of now, sales total 2,248 M while income totals -278,160 K. Its latest quarter income was 593,170 K while its last quarter net income were -83,760 K.
